Cullinan Therapeutics announced its third quarter 2026 financial results, highlighting $313.8 million in cash and investments, providing a runway into 2029. The company is progressing multiple clinical trials for T cell engager therapies targeting autoimmune diseases and cancers, including ongoing studies for CLN-978 in lupus and rheumatoid arthritis, a global Phase 1/2 study of velinotamig in autoimmune cytopenias, and a Phase 2 study of CLN-049 in relapsed/refractory AML. Additionally, the NDA submission for zipalertinib in first-line EGFR ex20ins NSCLC is underway with completion expected in November. Cullinan plans to share updated clinical data in December and at the ASH Annual Meeting, positioning itself strongly in the T cell engager space with upcoming regulatory and clinical milestones.
Cullinan Therapeutics' latest update notes $313.8 million in cash and investments, supporting operations through 2029. For readers following the health sector, here is Pluang's market snapshot as of Nov 10, 2026 18:42 WIB: out of 150 priced US health stocks, 85 rose and 56 fell. Notable movers include AbCellera Biologics Inc (ABCL) at USD 12.96 with a 1-day change of +3.68% and a typical hold time on Pluang of 42 days, Liquidia Corporation (LQDA) at USD 49.03 with a +2.42% change, and Maravai LifeSciences Holdings Inc. (MRVI) at USD 7.83 down -2.37%.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
